Skip to content
OpenCapital
Get started

Apogee Therapeutics, Inc. APGE Q4 2025 Annual earnings

Reported March 2, 2026 · Before market open

EPS-$1.03Beat by $0.02
EPS estimate-$1.05

Next report

Aug 10, 2026 (In 1 week)
Revenue estimate$10.0M
EPS estimate-$1.10

Financials

Q4 2025

Income statement

See full
Operating income-$78.1M-2.9%
Net income-$69.4M-3.2%
EPS (diluted)-$1.03+13.4%

Balance sheet

See full
Cash & equivalents$131.5M-7.2%
Total debt$8.8M-25.2%
Total assets$937.1M+24.3%

Cash flow

See full
Operating cash flow-$62.7M+7.4%
CapEx$62.0K—
Free cash flow-$62.8M+7.3%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$5.16B+100%
Enterprise value$5.03B+106%

Returns & leverage

See full
Current ratio26.6×+8.0×

Versus estimates

Diluted EPS

Q1 2026-$1.06Beat by $0.06
Q4 2025-$1.03Beat by $0.02
Q3 2025-$1.11Beat by $0.01Q2 2025-$1.13Miss by $0.10Q1 2025-$0.95Beat by $0.24Q4 2024-$1.19Miss by $0.25

Ask the moment Apogee Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Apogee Therapeutics, Inc. report Q4 2025 earnings?
Apogee Therapeutics, Inc. (APGE) reported Q4 2025 earnings on March 2, 2026 before market open.
What were Apogee Therapeutics, Inc.'s Q4 2025 revenue and EPS?
Apogee Therapeutics, Inc. reported eps of $-1.03 for Q4 2025.
Did Apogee Therapeutics, Inc. beat estimates in Q4 2025?
EPS beat the consensus estimate of $-1.05 by $0.02.
How did Apogee Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 13.4% from $-1.19.
Where can I find Apogee Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001974640-26-000001) and the 10-K periodic report (0001974640-26-000002) directly on SEC EDGAR. The filing index links above go to sec.gov.